SCHEMBL6236364

SCHEMBL6236364

c1ccc(CCNc2ccnc(Nc3ccc4[nH]ncc4c3)n2)nc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.58
PTK2 Q05397 1/20 0.57
PTK2B Q14289 1/20 0.57
IGF1R P08069 3/20 0.56
PLK1 P53350 3/20 0.56
MAPKAPK2 P49137 3/20 0.56
ROCK2 O75116 3/20 0.56
SYK P43405 3/20 0.56
PLK4 O00444 2/20 0.56
CHEK1 O14757 2/20 0.56
MAPK13 O15264 2/20 0.56
PDPK1 O15530 2/20 0.56
DAPK3 O43293 2/20 0.56
DYRK3 O43781 2/20 0.56
JAK2 O60674 2/20 0.56
PRKD3 O94806 2/20 0.56
MAP4K4 O95819 2/20 0.56
PAK4 O96013 2/20 0.56
CHEK2 O96017 2/20 0.56
EGFR P00533 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6262359 0.92 KDR (0.56) KDRPTK2PTK2BIGF1RPLK1
SCHEMBL6259622 0.90 PTK2 (0.67) KDRPTK2PTK2BIGF1RPLK1
SCHEMBL6260019 0.88 PTK2 (0.52) KDRPTK2PTK2BIGF1RPLK1
Ammonia Solution, Strong SCHEMBL6833389 0.85 PTK2 (0.58) KDRPTK2PTK2BIGF1RPLK1
SCHEMBL6260739 0.84 EGFR (0.49) KDRPTK2PTK2BSYKJAK2
SCHEMBL6210787 0.83 PTK2 (0.64) KDRPTK2PTK2BROCK2SYK
SCHEMBL6214284 0.83 PTK2 (0.61) KDRPTK2PTK2BIGF1RROCK2
SCHEMBL6210226 0.83 PTK2 (0.61) KDRPTK2PTK2BIGF1RPAK4
SCHEMBL6209160 0.82 AURKA (0.59) PLK1SYKJAK3DYRK1ASTK17A
SCHEMBL6239489 0.81 KDR (0.57) KDRPTK2PTK2BIGF1RPLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP claimed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US claimed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO claimed
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP disclosed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US disclosed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220177-A1 Compound for the treatment of abnormal cell growth CCNA1, CCNB1, CCNT1 KDR 741/4885PTK2 3004/4885PTK2B 1941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.